Clinical Trials

At MannKind, our commitment to clinical trials underscores our unwavering dedication to the well-being and safety of patients, along with our unrelenting pursuit of medical innovation. By dedicating substantial time, resources, and expertise to the meticulous execution of rigorous clinical trials, we firmly uphold the highest standards of scientific integrity.



Clinical trials lie at the heart of MannKind’s pursuit to transform medical potential into tangible progress. Each trial illuminates the path toward more effective treatments and therapies. Through meticulous testing and observation, focused on ensuring safety, we uncover the insights that shape medical breakthroughs. At MannKind, our commitment to clinical trials echoes our commitment to humanity, as we work tirelessly to elevate healthcare standards and pave the way for a safer, healthier, and more equitable future.


At MannKind, our unwavering commitment to safety and diversity in clinical trials is rooted in both science and compassion. We understand that behind every data point lies a person with a unique story, a journey, and a hope for better health. By intentionally embracing individuals from various backgrounds, ethnicities, ages, and genders in our participant pool, we aim to ensure that our research resonates the full gamut of individuals who will benefit from our medical products, all while prioritizing their safety. It’s a pursuit grounded not only in scientific integrity but also in empathy. By welcoming voices from all corners of society, we aim to foster a more inclusive and equitable future, where medical progress leaves no one behind. Through our collective efforts, we aspire to make a genuine difference in the lives of people everywhere.

INHALE-1 is a Phase 3, randomized controlled trial in children and teenagers ages 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin vs. multiple daily injections of rapid acting, in combination with basal insulin.
learn more
INHALE-3 is a phase 4, randomized controlled trial to evaluate efficacy and safety of inhaled insulin combined with basal insulin versus usual care in adults with type 1 diabetes (T1D). Participants will either continue their usual care or adopt an insulin regimen of basal injections plus inhaled insulin. Both groups will utilize a continuous glucose monitoring (CGM) system to assess glucose control.
learn more

Endocrine Scientific Advisory Board

Thomas C. Blevins, MD, ECNU, FACE, FNLA

-Endocrinologist at Texas Diabetes and Endocrinology (Austin)

Bruce W. Bode, MD, FACE

-Diabetes specialist, president and CEO of Atlanta Diabetes Associates (Atlanta)
-Clinical Associate Professor in the Department of Medicine at Emory University

Anders L Carlson, MD

-Investigator for the International Diabetes Center at Park Nicollet (Minneapolis)
-Associate Professor at the University of Minnesota Medical School

Eda Cengiz, MD, MHS

-Professor of Pediatrics at the University of California San Francisco School of Medicine (San Francisco)
-Benioff UCSF Professor in Children’s Health
-Director of the UCSF Pediatric Diabetes Program

Michael Haller, MD, MS-CI

-Professor and Chief of Pediatric Endocrinology at the University of Florida (Gainesville, FL)

Davida Kruger, MSN, APN-BC, BC-ADM

-Certified nurse practitioner at Henry Ford Health System (Detroit)
-Division of Endocrinology, Diabetes, Bone and mineral disease
-Director of Clinical Research
-Supervisor Advanced Practice Providers

Kashif Latif, MD

-Medical Director and Principal Investigator for AM Diabetes and Endocrinology Center (Bartlett, TN)

Janet B. McGill, MD, MA, FACE, FACP

-Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine (St. Louis)
-Attending Physical at Barnes-Jewish Hospital

Joanna Mitri, MD, MS

-Research Associate and Staff Physician at Joslin Diabetes Center (Boston)
-Assistant Professor at Harvard Medical School
-Medical Director of the Global Education and Advisory Division at JDC


Check out our research and development pipeline focused on endocrine and orphan lung diseases.

explore our products & pipeline

See how our technologies and therapies can help more people take control of their health.

view publications